Richmond Pharmacology Confirm event with the Department of International Trade

Posted:

August 2018

Richmond Pharmacology is delighted to confirm an upcoming event alongside the Department of International Trade in the US.Early Phase Drug Development in the UK is to take place Friday 28th of September in Boston, MA.

Click here to RSVP

The event which is to host speakers from both Richmond Pharmacology and UK regulators continues a long line of events staged between Richmond Pharmacology and the DIT around the world. Full details found below including how to express interest in attending the event.

Friday, 28 September 2018Time TBC

Café ArtScience650 East Kendall St,Cambridge, MA 02142

Click here to RSVP

Full schedule to follow, please email j.wilmott@richmondphramacology.com confirm interest in attending.

Supported By:

Back to news

More about us Adaptive Phase I, II & III Bridging Studies TQT Studies Patient Recruitment

Meet the experts

Richmond Pharmacology has a team of experts with extensive knowledge of clinical research trials.

Latest Publications

View our latest peer-reviewed publications from a selection of our clinical trials.

Latest Videos

Learn more about Richmond Pharmacology by viewing some of our videos.

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021

Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.

View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021

Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses.

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021

J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021

Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.